Examining the Common Challenges of RNAi Therapies in Immunology and Fibrosis to Improve Targeted Delivery and Increase Biodistribution

• Engineering immune cell and fibroblast-targeted LNPs or antibodies to deliver RNAi payloads, reducing cytokine-driven inflammation in autoimmune disorders
• Co-administering siRNA to produce better a therapeutic response
• Optimizing biodistribution for fibrotic tissues via novel chemistries, reversing organ fibrosis with localized effects

Speakers:

Andrew Coles

Scientist

Abbvie